Why Pharmaron Beijing Co., Ltd. (SZSE:300759) Could Be Worth Watching
Mar 17
Have your own idea? Try our Stock Screener
Chinese (SSE) Life Sciences Industry Analysis
UpdatedMar 21, 2025
DataAggregated Company Financials
Companies26
- 7D6.4%
- 3M16.0%
- 1Y21.7%
- YTD24.6%
In the last week, the Life Sciences industry is up 6.8%, with WuXi AppTec up 14%. During this same period, the MGI Tech underperformed, falling 6.6%. This means that the industry has gained 21% over the past year. Earnings are forecast to grow by 36% annually.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 21 Mar 2025 | CN¥454.3b | CN¥89.7b | CN¥12.7b | 43.7x | 35.7x | 5.1x |
| Sun, 16 Feb 2025 | CN¥411.8b | CN¥88.1b | CN¥11.2b | 42x | 36.6x | 4.7x |
| Tue, 14 Jan 2025 | CN¥349.9b | CN¥86.9b | CN¥11.1b | 32x | 31.5x | 4x |
| Thu, 12 Dec 2024 | CN¥401.3b | CN¥87.8b | CN¥11.2b | 41.7x | 35.9x | 4.6x |
| Sat, 09 Nov 2024 | CN¥397.3b | CN¥87.8b | CN¥11.2b | 41.7x | 35.5x | 4.5x |
| Mon, 07 Oct 2024 | CN¥386.6b | CN¥88.2b | CN¥12.4b | 35.3x | 31.2x | 4.4x |
| Wed, 04 Sep 2024 | CN¥275.0b | CN¥87.1b | CN¥12.3b | 27.6x | 22.4x | 3.2x |
| Fri, 02 Aug 2024 | CN¥295.8b | CN¥87.7b | CN¥12.5b | 26.7x | 23.6x | 3.4x |
| Sun, 30 Jun 2024 | CN¥279.1b | CN¥88.3b | CN¥13.4b | 24.7x | 20.8x | 3.2x |
| Tue, 28 May 2024 | CN¥313.4b | CN¥88.3b | CN¥13.4b | 28.3x | 23.4x | 3.5x |
| Thu, 25 Apr 2024 | CN¥307.6b | CN¥90.5b | CN¥15.0b | 29.9x | 20.5x | 3.4x |
| Sat, 23 Mar 2024 | CN¥345.2b | CN¥90.4b | CN¥15.6b | 33.9x | 22.1x | 3.8x |
| Mon, 19 Feb 2024 | CN¥346.7b | CN¥91.1b | CN¥16.1b | 29.9x | 21.6x | 3.8x |
| Wed, 17 Jan 2024 | CN¥458.5b | CN¥91.1b | CN¥16.1b | 36.6x | 28.5x | 5x |
| Fri, 15 Dec 2023 | CN¥481.5b | CN¥91.1b | CN¥16.1b | 37.1x | 29.9x | 5.3x |
| Sun, 12 Nov 2023 | CN¥558.5b | CN¥91.1b | CN¥16.1b | 40.5x | 34.7x | 6.1x |
| Tue, 10 Oct 2023 | CN¥517.9b | CN¥92.0b | CN¥18.3b | 35.4x | 28.2x | 5.6x |
| Thu, 07 Sep 2023 | CN¥477.5b | CN¥91.8b | CN¥18.3b | 33.5x | 26.1x | 5.2x |
| Sat, 05 Aug 2023 | CN¥495.8b | CN¥91.8b | CN¥18.5b | 35.6x | 26.8x | 5.4x |
| Mon, 03 Jul 2023 | CN¥448.5b | CN¥91.3b | CN¥18.5b | 34.3x | 24.3x | 4.9x |
| Wed, 31 May 2023 | CN¥490.8b | CN¥91.3b | CN¥18.5b | 37.9x | 26.6x | 5.4x |
| Fri, 28 Apr 2023 | CN¥507.6b | CN¥91.4b | CN¥19.1b | 46x | 26.6x | 5.6x |
| Sun, 26 Mar 2023 | CN¥584.2b | CN¥90.2b | CN¥19.9b | 49.1x | 29.4x | 6.5x |
| Tue, 21 Feb 2023 | CN¥637.4b | CN¥86.6b | CN¥20.8b | 54.3x | 30.6x | 7.4x |
| Thu, 19 Jan 2023 | CN¥687.4b | CN¥86.6b | CN¥20.8b | 56.2x | 33x | 7.9x |
| Sat, 17 Dec 2022 | CN¥579.8b | CN¥86.6b | CN¥20.8b | 48.6x | 27.9x | 6.7x |
| Mon, 14 Nov 2022 | CN¥628.1b | CN¥86.5b | CN¥20.8b | 55.3x | 30.2x | 7.3x |
| Wed, 12 Oct 2022 | CN¥506.9b | CN¥78.2b | CN¥16.9b | 44.7x | 29.9x | 6.5x |
| Fri, 09 Sep 2022 | CN¥558.7b | CN¥73.8b | CN¥16.5b | 48.7x | 33.8x | 7.6x |
| Sun, 07 Aug 2022 | CN¥656.0b | CN¥73.3b | CN¥17.1b | 67.6x | 38.4x | 9x |
| Tue, 05 Jul 2022 | CN¥733.2b | CN¥69.0b | CN¥15.2b | 73x | 48.3x | 10.6x |
| Thu, 02 Jun 2022 | CN¥589.3b | CN¥69.0b | CN¥15.2b | 54.4x | 38.8x | 8.5x |
| Sat, 30 Apr 2022 | CN¥619.9b | CN¥67.5b | CN¥15.1b | 59x | 41.1x | 9.2x |
| Mon, 28 Mar 2022 | CN¥663.3b | CN¥62.7b | CN¥15.0b | 67.6x | 44.2x | 10.6x |
Price to Earnings Ratio
44.2x
Current Industry PE
- Investors are optimistic on the Chinese Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 36.3x which is higher than its 3-year average PE of 30.2x.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 5.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 5.3% per year over the last three years.
- Meanwhile revenues for these companies have grown 13% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 1.53% | |
| Healthcare | 1.91% | |
| Life Sciences | 6.43% | |
| Clinical Research and Equipment | 6.43% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥66.98 | 4.8% +CN¥8.9b | 39.8% | PE20.5x | |
| 688068 Beijing Hotgen Biotech | CN¥91.33 | 9.7% +CN¥724.7m | 183.2% | PS16x | |
| 688621 Beijing Sun-Novo Pharmaceutical Research | CN¥44.80 | 2.0% +CN¥98.6m | -23.8% | PE27.8x | |
| 301257 SMO ClinPlusLTD | CN¥32.65 | 3.7% +CN¥92.2m | -17.9% | PE24.5x | |
| 688758 Suzhou Sepax Technologies | CN¥17.75 | 1.3% +CN¥91.6m | n/a | PE86.8x |
